Macquarie Group LTD Agenus Inc Transaction History

Macquarie Group LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.14 $16,191 - $25,939	-8,261 Reduced 52.73%	7,407 $32,000
Q4 2021 Feb 11, 2022	BUY	$2.92 - $5.74 $17,931 - $35,249	6,141 Added 64.46%	15,668 $50,000
Q2 2021 Aug 13, 2021	BUY	$2.56 - $5.49 $16,000 - $34,312	6,250 Added 190.72%	9,527 $52,000
Q1 2021 May 14, 2021	SELL	$2.69 - $5.25 $2,703 - $5,276	-1,005 Reduced 23.47%	3,277 $9,000
Q2 2020 Aug 11, 2020	BUY	$2.29 - $4.24 $9,805 - $18,155	4,282 New	4,282 $17,000
Q1 2019 May 15, 2019	SELL	$2.51 - $3.73 $23,091 - $34,316	-9,200 Closed	0 $0
Q4 2018 Feb 15, 2019	SELL	$1.59 - $2.66 $6,837 - $11,438	-4,300 Reduced 31.85%	9,200 $22,000
Q3 2018 Nov 15, 2018	BUY	$1.59 - $2.42 $21,465 - $32,670	13,500 New	13,500 $29,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.